Lilly to seek accelerated FDA approval for Alzheimer's drug this year
Eli Lilly said on Thursday it will apply for U.S. health regulator's accelerated approval this year for its experimental Alzheimer's drug, weeks after Biogen Inc's (BIIB.O) controversial drug for the disease was approved.
Comments
Post a Comment
Leave a comment. Thanks!
Comentarios de Facebook